The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Cited by (614)

Items 101–200 of 614

1. The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies
   Oliviero Marinelli, Daniela Annibali, Cristina Aguzzi, Sandra Tuyaerts, Frédéric C. Amant, Maria Beatrice Morelli, Giorgio Santoni, Consuelo Amantini, Federica Maggi, Massimo Nabissi · 2019 · Frontiers in Oncology
2. Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype
   Soumaya Allouch, Ishita Gupta, Shaza Malik, Halema F. Al Farsi, Semir Vranić, Ala‐Eddin Al Moustafa · 2020 · Frontiers in Oncology
3. PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
   Xintong Lyu, Miao Zhang, Guang Li, Yuan-Jun Jiang, Q. Qiao · 2019 · Journal of Cancer
4. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
   Yucai Wang, Kerstin Wenzl, Michelle K. Manske, Yan W. Asmann, Vivekananda Sarangi, Patricia Theresa Greipp, Jordan Edward Krull, Keenan T. Hartert, Rong Lucy He, Andrew L. Feldman et al. · 2019 · Blood Cancer Journal
5. CSNK2 in cancer: pathophysiology and translational applications
   Scott W. Strum, Laszlo Gyenis, David W. Litchfield · 2021 · British Journal of Cancer
6. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
   Changling Gu, Haixia Zhu, Lan Deng, Xiaoqing Meng, Kai Li, Wei Xu, Le Zhao, Yueqin Liu, Zhenping Zhu, Haomin Huang · 2021 · Acta Pharmacologica Sinica
7. Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression
   Jian Lu, Jing Wu, Lingxiang Mao, Huaxi Xu, Shengjun Wang · 2022 · Cytokine & Growth Factor Reviews
8. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases
   Irene García‐Díez, Eugenia Hernández-Ruiz, Evelyn Andrades, Javier Gimeno, Carla Ferrándiz‐Pulido, Mireia Yébenes, Vicente García‐Patos, Ramon Maria Pujol, Inmaculada Hernández‐Muñoz, Agustí Toll · 2018 · American Journal of Dermatopathology
9. High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome
   Peter Hollander, Peter Kamper, Karin Ekstrom Ekstroem Smedby, Gunilla Enblad, Maja Ludvigsen, Julie Bondgaard Mortensen, Rose‐Marie Amini, Stephen Jacques Hamilton-Dutoit, Francesco d’Amore, Daniel Molin et al. · 2017 · Blood Advances
10. Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
    Anne M. Macpherson, Simon Charles Barry, Carmela Ricciardelli, Martin Klaus Oehler · 2020 · Journal of Clinical Medicine
11. Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases
    Amke C. Beenen, Tatjana Sauerer, Niels Schaft, Jan Dörrie · 2022 · International Journal of Molecular Sciences
12. PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications
    Salvatore Ulisse, Chiara Tuccilli, Salvatore Sorrenti, Alessandro Antonelli, Poupak Fallahi, Eleonora D’Armiento, A Catania, Francesco Tartaglia, Maria Ida Amabile, Laura Giacomelli et al. · 2019 · International Journal of Molecular Sciences
13. Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1
    Ganji Purnachandra Nagaraju, Rama Rao Malla, Riyaz M. Basha, Ion G. Motofei · 2021 · Seminars in Cancer Biology
14. Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
    Michelle Coureau, Anne‐Pascale Meert, Thierry Berghmans, Bogdan Dragoş Grigoriu · 2020 · Frontiers in Medicine
15. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer
    Yongbo Kang, Yue Cai · 2021 · World Journal of Gastroenterology
16. The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis
    Mária Wozniaková, Jozef Škarda, Milan Raška · 2022 · Pathology & Oncology Research
17. Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection
    Maike Sperk, Robert van Domselaar, Ujjwal Neogi · 2018 · International Journal of Molecular Sciences
18. Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
    Marilina García‐Aranda, Maximino Redondo · 2019 · International Journal of Molecular Sciences
19. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
    Sitanshu S. Singh, Achyut Dahal, Leeza Shrestha, Seetharama D. S. Jois · 2019 · Current Medicinal Chemistry
20. Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments
    Romi Gupta, Raj Kumar, Courtney A. Penn, Narendra Wajapeyee · 2025 · Trends in Immunology
21. Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis
    Karin Wadström, L. Jacobsson, Aladdin J Mohammad, Kenneth J. Warrington, Eric L. Matteson, Carl Turesson · 2020 · Lara D. Veeken
22. PD-1 signaling pathway in sepsis: Does it have a future?
    Rongping Chen, Lixin Zhou · 2021 · Clinical Immunology
23. Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
    Jihane Boustani, Benoît Lecoester, Jérémy Baude, Charlène Latour, Olivier Adotévi, Céline Mirjolet, Gilles Truc · 2021 · Cancers
24. PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions
    Liren Jiang, Ning Zhang, Siteng Chen, Jing He, Yonghua Liu, Ya-Qin Han, Xiaoqin Shi, Jiji Yang, Dong-Yun Mu, Guo‐Hui Fu et al. · 2021 · Frontiers in Oncology
25. PD-L1 maintains neutrophil extracellular traps release by inhibiting neutrophil autophagy in endotoxin-induced lung injury
    Cheng‐long Zhu, Jian Xie, Zhenzhen Zhao, Peng Li, Qiang Liu, Yu Guo, Yan Meng, Xiaojian Wan, Jinjun Bian, Xiaoming Deng et al. · 2022 · Frontiers in Immunology
26. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
    Yong-Qiang Ao, Jian Gao, Shuai Wang, Jia-Hao Jiang, Jie Deng, Haikun Wang, Bei Xu, Jian‐Yong Ding · 2023 · Molecular Cancer
27. Pathogenesis of polymyalgia rheumatica
    Giuliana Guggino, Angelo Ferrante, Federica Macaluso, G Triolo, Francesco Ciccia · 2018 · Reumatismo
28. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
    Matthew Labriola, Kristen A. Batich, Jason Zhu, Megan Ann McNamara, Michael Roger Harrison, Andrew J. Armstrong, Daniel J. George, Tian Zhang · 2019 · Clinical Genitourinary Cancer
29. The PD‐1 Interactome
    Wang, Qi, Bardhan, Kankana, Boussiotis, Vassiliki A., Patsoukis, Nikolaos · 2021 · Advanced Biology
30. The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy
    Md Rakibul Alam, Md Mizanur Rahman, Zhiguo Li · 2023 · Genes & Diseases
31. Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers
    Wang Zhang, Anoop T. Ambikan, Maike Sperk, Robert van Domselaar, Piotr Nowak, Kajsa Noyan, Aman Russom, Anders B. Sönnerborg, Ujjwal Neogi · 2017 · EBioMedicine
32. Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
    Federica Miglietta, Gaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci · 2019 · The Oncologist
33. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer
    Boris I. Chobrutskiy, Andrea Chobrutskiy, Saif Zaman, Michelle G. Yeagley, Taha I. Huda, George Blanck · 2021 · Molecular Immunology
34. Molecular Control of Follicular Helper T cell Development and Differentiation
    Haijing Wu, Yaxiong Deng, Ming Zhao, Jianzhong Zhang, Min Zheng, Genghui Chen, Linfeng Li, Zhibiao He, Qianjin Lu · 2018 · Frontiers in Immunology
35. Neutrophils Which Migrate to Lymph Nodes Modulate CD4+ T Cell Response by a PD-L1 Dependent Mechanism
    Sofía Daiana Castell, María Florencia Harman, Gabriel Morón, Belkys Angélica Maletto, María Cristina Pistoresi-Palencia · 2019 · Frontiers in Immunology
36. Influence of age on stem cells depends on the sex of the bone marrow donor
    Michael Selle, Johanna Dorothea Koch, Alina Ongsiek, Linnea Ulbrich, Weikang Ye, Zhida Jiang, Christian Krettek, Claudia Neunaber, Sandra Noack · 2022 · Journal of Cellular and Molecular Medicine
37. Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population
    Sara Falahi, Mohammad Hossein Zamanian, Parisa Feizollahi, Alireza Rezaiemanesh, Farhad Salari, Zahra Mahmoudi, Ali Gorgin Karaji · 2022 · Cytokine
38. T‐cells expressing a chimeric‐PD1‐Dap10‐CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer
    Geoffrey Parriott, Kelsey Deal, Shane Crean, Elle Richardson, Emily Nylen, Amorette E. Barber · 2020 · Immunology
39. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
    Vishakha Singh, Amit Khurana, Prince Allawadhi, Anil Kumar Banothu, Kala Kumar Bharani, Ralf Weiskirchen · 2021 · Frontiers in Pharmacology
40. Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2′-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors
    Hua Zhang, Shijia Zhou, Jacek Plewka, Caiyun Wu, Mengyu Zhu, Qimeng Yu, Bogdan Musielak, Xiao Wang, Annoor Awadasseid, Katarzyna Magiera‐Mularz et al. · 2023 · Journal of Medicinal Chemistry
41. Emerging role of PD-L1 modification in cancer immunotherapy.
    Xiaoli Hu, Zixia Lin, Zhiwei Peter Wang, Qiangyong Zhou · 2021 · PubMed Central
42. Refining patient selection for breast cancer immunotherapy: beyond PD-L1
    Kossai, M., Radosevic-Robin, N., Penault-Llorca, F. · 2021 · ESMO Open
43. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2)
    Maria Domenica Castellone, Rosa Marina Melillo · 2017 · Endocrine Related Cancer
44. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
    Naofumi Mukaida, Yasunari Nakamoto · 2018 · World Journal of Gastroenterology
45. Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
    Durre Aden, Samreen Zaheer, Niti Sureka, Monal Trisal, Jai Kumar Chaurasia, Sufian Zaheer · 2025 · Pathology - Research and Practice
46. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Thaiz Rivera Vargas, Lionel Apétoh · 2019 · Frontiers in Immunology
47. PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function
    Tongfeng Liu, Shuwen Cheng, Bo Peng, Haojing Zang, Xiaofeng Zhu, Xuetong Wang, Xujie Zhao, Yinmin Gu, Yongbo Pan, Hongbo Hu et al. · 2024 · Cell Death and Disease
48. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals
    Javier Arranz‐Nicolás, Jesús Ogando, Denise Soutar, Raquel Arcos, Daniel Meraviglia-Crivelli, Santos Mañes, Isabel Mérida, Antonia Ávila‐Flores · 2018 · Cancer Immunology Immunotherapy
49. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma
    Nora Wuerdemann, Sibel Elif Gültekin, Katharina Pütz, Claus Wittekindt, Christian Ulrich Huebbers, Shachi Jenny Sharma, Hans Nikolaus Caspar Eckel, Anna B. Schubotz, Stefan Gattenlöhner, Reinhard Büttner et al. · 2020 · International Journal of Molecular Sciences
50. TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments
    Yuan-Li Tsai, Marcel Arias-Badia, Theresa A. Kadlecek, Yee May Lwin, Aahir Srinath, Neel H. Shah, Zhi‐En Wang, Diane L. Barber, John Kuriyan, Lawrence H. Fong et al. · 2023 · Immunity
51. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors
    Xingxing Yuan, Zujun Sun, Qingyun Yuan, Weihua Hou, Qiaoyan Liang, Yu-Xiong Wang, Wei Mo, Huijie Wang, Min Yu · 2020 · Investigational New Drugs
52. UEG Week 2018 Poster Presentations
    Pittet, V., Aslan, N., Fournier, N., Decollogny, A., Schoepfer, A., Seibold, F., Rodondi, P.Y. · 2018 · United European Gastroenterology Journal
53. The relationship between autophagy and PD-L1 and their role in antitumor therapy
    Yu Cui, Jinfeng Shi, Youbin Cui, Zhanpeng Zhu, Wei Zhu · 2023 · Frontiers in Immunology
54. Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1
    Asha M. Rudjord-Levann, Zilu Ye, Lise Hafkenscheid, Sabrina Horn, Renske Wiegertjes, Mathias Ingemann Nielsen, Ming Song, Caroline Benedicte Kjærulff Mathiesen, Jesse Stoop, Sean R. Stowell et al. · 2023 · iScience
55. Tumor‐derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
    Yunjiao Wu, Huichao Fu, Jingwei Hao, Zhaoyang Yang, Xinyi Qiao, Yingjie Li, Rui Zhao, Tie Lin, Yicun Wang, Meng Wang · 2024 · Frontiers in Immunology
56. PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1–Infected Corneas
    Sohyun Jeon, Alexander M. Rowe, Kate L. Carroll, Stephen A K Harvey, Robert L. Hendricks · 2018 · The Journal of Immunology
57. CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1+ viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion
    Rafael Correa‐Rocha, Jacobo López‐Abente, Carolina Gutiérrez, Verónica Astrid Pérez-Fernández, Adrián Prieto-Sánchez, Santiago Moreno, María Ángeles Muñoz‐Fernández, Marjorie Pion · 2018 · PLoS ONE
58. Aberrant protein glycosylation in cancer: implications in targeted therapy
    Joana G. Rodrigues, Henrique O. Duarte, Celso Albuquerque Reis, Joana Gomes · 2021 · Biochemical Society Transactions
59. Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
    Poyee Lau, Guanxiong Zhang, Shuang Zhao, Long Liang, Hailun Zhang, Guowei Zhou, Mien‐Chie Hung, Xiang Chen, Hong Liu · 2022 · Cellular and Molecular Immunology
60. Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
    Huixin Zhang, Lysa Houadj, Kevin Yang Wu, Simon D. Tran · 2024 · Diagnostics
61. Pembrolizumab for anaplastic thyroid cancer: a case study
    Marra Jai Aghajani, Adam James Cooper, Helen Marie McGuire, Thomas C. Jeffries, Jawad Saab, Kasim Ismail, Paul DE SOUZA, Victoria Bray, Barbara Fazekas de St Groth, Navin Niles et al. · 2019 · Cancer Immunology Immunotherapy
62. ADAM12 is a costimulatory molecule that determines Th1 cell fate and mediates tissue inflammation
    Yawei Liu, Robert Bockermann, Mahdieh Hadi, Iman Safari, Belinda Carrion, Marie Kveiborg, Shohreh Issazadeh‐Navikas · 2020 · Cellular and Molecular Immunology
63. Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications
    Anne M. van Harten, Ruud H. Brakenhoff · 2021 · Cancers
64. The 3.0 Cell Communication: New Insights in the Usefulness of Tunneling Nanotubes for Glioblastoma Treatment
    Lorenzo Taiarol, Beatrice Formicola, Stefano Fagioli, Giulia Sierri, Alessia D’Aloia, Marcelo Kravicz, Antonio Renda, Francesca Viale, Roberta Dal Magro, Michela Ceriani et al. · 2021 · Cancers
65. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
    Kah Yee Goh, Terence You De Cheng, Su Chin Tham, Wan‐Teck Lim · 2023 · Biomedicines
66. Role of immune microenvironment in gastrointestinal stromal tumours
    Andrew M. Blakely, Andrés Matoso, Pallavi A Patil, Ross Taliano, Jason T. Machan, Thomas J. Miner, Kara A. Lombardo, Murray B. Resnick, Lijuan Wang · 2017 · Histopathology
67. Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
    Manuel Weber, Falk Wehrhan, Christoph Baran, Abbas Agaimy, Maike J. Büttner-Herold, Marco Rainer Kesting, Jutta Ries · 2019 · Cancer Medicine
68. Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
    Heli Vajavaara, Julie Bondgaard Mortensen, Suvi‐Katri Leivonen, Ida Monrad Hansen, Maja Ludvigsen, Harald Holte, Judit Meszaros Jørgensen, Mette Bjerre, Francesco d’Amore, Sirpa Leppä · 2021 · Cancers
69. FCGR1A Serves as a Novel Biomarker and Correlates With Immune Infiltration in Four Cancer Types
    Ji-li Xu, Yong Guo · 2020 · Frontiers in Molecular Biosciences
70. A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
    Negar Hosseinkhani, Mahdi Abdoli Shadbad, Mohammad Asghari Jafarabadi, Noora Karim Ahangar, Zahra Asadzadeh, Seyede Momeneh Mohammadi, Parisa Lotfinejad, Nazila Alizadeh, Oronzo Brunetti, Rossella Fasano et al. · 2021 · International Journal of Molecular Sciences
71. Possible Role of Matrix Metalloproteinases and TGF-β in COVID-19 Severity and Sequelae
    Gustavo Ramírez-Martínez, Luis Armando Jiménez-Álvarez, Alfredo Cruz‐Lagunas, Sergio Ignacio-Cortés, Itzel Alejandra Gómez-García, Tatiana Sofia Rodrı́guez-Reyna, José Alberto Choreño-Parra, Joaquı́n Zúñiga · 2022 · Journal of Interferon & Cytokine Research
72. Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions
    Jérôme Thiery · 2022 · Exploration of Targeted Anti-tumor Therapy
73. Adoptive transfer of murine T cells expressing a chimeric‐ PD 1‐Dap10 receptor as an immunotherapy for lymphoma
    Adam Lynch, William Hawk, Emily Nylen, Sean Ober, Pierre Autin, Amorette E. Barber · 2017 · Immunology
74. Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology
    Elena Muraro, Rebecca Romanò, Giuseppe Fanetti, Emanuela Vaccher, Irene Turturici, Valentina Lupato, Fabio Biagio La Torre, Jerry Polesel, Elisabetta Fratta, Vittorio Giacomarra et al. · 2022 · Critical Reviews in Oncology/Hematology
75. Mesenchymal Stem Cells Derived and Cultured from Glioblastoma Multiforme Increase Tregs, Downregulate Th17, and Induce the Tolerogenic Phenotype of Monocyte-Derived Cells
    Kalina D. Tumangelova-Yuzeir, E. Naydenov, Ekaterina Ivanova‐Todorova, Ekaterina Krasimirova, Georgi Vasilev, S Nachev, Dobroslav Stanimirov Kyurkchiev · 2019 · Stem Cells International
76. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1
    Wenjie Zhai, Xiuman Zhou, Jiangfeng Du, Yanfeng Gao · 2019 · Methods in enzymology on CD-ROM/Methods in enzymology
77. Leishmania Parasites Drive PD-L1 Expression in Mice and Human Neutrophils With Suppressor Capacity
    Alessandra Marcia da Fonseca-Martins, Phillipe de Souza Lima-Gomes, Maísa Mota Antunes, Renan Garcia de Moura, Luciana Polaco Covre, Carolina Calôba, Vivian Grizente Rocha, Renata M. Pereira, Gustavo Batista Menezes, Daniel Cláudio Oliveira Gomes et al. · 2021 · Frontiers in Immunology
78. Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
    Lingrong Hu, Chengliang Sun, Kai Yuan, Peng Yang · 2024 · Drug Discovery Today
79. Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer
    Gaber Plavc, Tanja Jesenko, Miha Oražem, Primož Strojan · 2020 · Cancers
80. Ultrasensitive detection of programmed death-ligand 1 (PD-L1) in whole blood using dispersible electrodes
    Parisa Moazzam, Munkhshur Myekhlai, Ali Alinezhad, Fida’a A. Alshawawreh, Padmavathy Bakthavathsalam, Vinícius R. Gonçales, Richard David Tilley, J. Justin Gooding · 2021 · Chemical Communications
81. Frailty Pathogenesis, Assessment, and Management in Older Adults With COVID-19
    Quan She, Bo Chen, Wen Liu, Min Li, Weihong Zhao, Jianqing Wu · 2021 · Frontiers in Medicine
82. Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling
    Panpan Ma, Xinxin Jin, Zhiwei Fan, Zhou Wang, Suhui Yue, Changyue Wu, Shiyin Chen, Yuanyuan Wu, Miaomiao Chen, Donghua Gu et al. · 2021 · Cancer Biology and Medicine
83. The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden
    Abdollah Jafarzadeh, Sunil Kumar, Neelam Prakash Bodhale, Sara Jafarzadeh, Maryam Nemati, Iraj Sharifi, Arup Sarkar, Bhaskar Saha · 2022 · Cytokine
84. Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study
    Sevinj Yolchuyeva, Elena Giacomazzi, M. Tonneau, Fabien C. Lamaze, M. Orain, F. Coulombe, J. Malo, W. Belkaid, B. Routy, P. Joubert et al. · 2023 · Scientific Reports
85. Molecular background of skin melanoma development and progression: therapeutic implications
    Magdalena Olbryt · 2019 · Advances in Dermatology and Allergology
86. A review of obstructive sleep apnea and lung cancer: epidemiology, pathogenesis, and therapeutic options
    Fang Yuan, Yanxia Hu, Fei Xu, Xujun Feng · 2024 · Frontiers in Immunology
87. Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
    Stijn De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey · 2021 · Cancers
88. Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer
    Sven Hans Petersen, Ley‐Fang Kua, Shotaro Nakajima, Wei Peng Yong, Koji Kono · 2021 · Scientific Reports
89. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
    Priyatharcini Kejamurthy, K. T. Ramya Devi · 2023 · Medical Oncology
90. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
    Sarra Mestiri, Dina Moustafa Abo El-Ella, Queenie Fernandes, Takwa Bedhiafi, Salam Almoghrabi, Shayista Akbar, Varghese Philipose Inchakalody, Laila Assami, Shaheena Anwar, Shahab Uddin M.S. et al. · 2024 · Biomedicine & Pharmacotherapy
91. The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma
    Peng Liao, Haofan Wang, Ya‐ling Tang, Ya-Jie Tang, Xin‐hua Liang · 2019 · Frontiers in Immunology
92. Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy
    S. D. Singh, Navneet Singh, Manoj Baranwal, Siddharth Sharma, Shilpa Devi, Sandeep Kumar · 2023 · 3 Biotech
93. T cell exhaustion and senescence for ovarian cancer immunotherapy
    Jiao Zhao, Zhongmiao Wang, Yingying Tian, Jing Ning, Huinan Ye · 2024 · Seminars in Cancer Biology
94. Smart CAR-T Nanosymbionts: archetypes and proto-models
    Juan C. Baena, Juan Sebastián Victoria, Alejandro Toro-Pedroza, Cristian C. Aragón, Joshua Ortiz‐Guzman, Juan Esteban García-Robledo, David Torres, Lady J. Ríos-Serna, Ludwig L. Albornóz, Joaquin D. Rosales et al. · 2025 · Frontiers in Immunology
95. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice
    Zhengping Hu, Liang Ye, Yingying Xing, Jinhang Hu, Tao Xi · 2018 · Scientific Reports
96. Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis
    Jennifer Kubon, Danijel Sikic, Markus Eckstein, Veronika Weyerer, Robert Stöhr, Angela Neumann, Bastian Keck, Bernd Wullich, Arndt Hartmann, Ralph Markus Wirtz et al. · 2020 · Cancers
97. Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
    Curtis A. Clark, Eddy Shih-Hsin Yang · 2021 · Frontiers in Oncology
98. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
    Andrea Palicelli, Martina Bonacini, Stefania Croci, Cristina Magi‐Galluzzi, Sofía Cañete‐Portillo, Alcides Chaux, Alessandra Bisagni, Eleonora Zanetti, Dario de Biase, Beatrice Melli et al. · 2021 · Cells
99. PD-L1 May Mediate T-Cell Exhaustion in a Case of Early Diffuse Leishmaniasis Caused by Leishmania (L.) amazonensis
    Daniel Holanda Barroso, Sarah de Athayde Couto Falcão, Jorgeth de Oliveira Carneiro da Motta, Laís Sevilha dos Santos, Gustavo Henrique Soares Takano, Ciro Martins Gomes, Cecilia Beatriz Fiuza Favali, Beatriz Dolabela de Lima, Raimunda Nonata Ribeiro Sampaio · 2018 · Frontiers in Immunology
100. Purinergic Signaling in Pancreas—From Physiology to Therapeutic Strategies in Pancreatic Cancer
     Ivana Novak, Haoran Yu, Lara Magni, Ganga Deshar · 2020 · International Journal of Molecular Sciences